Roche COVID-19 Response | Questions About Our Medicines? Visit medinfo.roche.com
ARTEMIS (CTONG 1509) Principle Investigator Interview Video
First phase III trial of bevacizumab +/- erlotinib in Chinese patients with 1L EGFR Mut+ NSCLC (CTONG 1509)
Please note; in some countries the combination of erlotinib plus bevacizumab may not be registered or reimbursed
Data of preparation February 2020- M-XX-00000785 - © 2020
This website is a global information resource. It is intended for healthcare professionals outside of the United States of America (US) the United Kingdom (UK), and Australia (AU) who are interested in information on TARCEVA®. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Prescribing Information for full details.